Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized, Parallel-Group, Single-Dose Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

NCT05292131 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT05292131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05292131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized, Parallel-Group, Single-Dose Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants
Lead sponsor
UCB Biopharma SRL
Phase
Phase 1
Overall status
Completed
Start date
March 17, 2022
Completion date
January 9, 2023
Enrollment
121 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy study participants